Addition of Infliximab to Standard Acute Graft-versus-Host Disease Prophylaxis Following Allogeneic Peripheral Blood Cell Transplantation

Infliximab, a chimeric monoclonal antibody against tumor necrosis factor-α, has shown activity against steroid refractory acute graft-versus-host disease (GVHD). We conducted a prospective trial of infliximab for the prophylaxis of acute GVHD. Patients older than 20 years undergoing myeloablative al...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Hamadani, Mehdi, Hofmeister, Craig C., Jansak, Buffy, Phillips, Gary, Elder, Patrick, Blum, William, Penza, Sam, Lin, Thomas S., Klisovic, Rebecca, Marcucci, Guido, Farag, Sherif S., Devine, Steven M.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2008
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4100722/
https://ncbi.nlm.nih.gov/pubmed/18541197
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2008.04.006
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak